Sputtr.com | Alternative Search Engine

Ambien

FULL PRESCRIBING INFORMATION

HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use AMBIEN safely and effectively. See full prescribing information for

Ambien (zolpidem tartrate) Tablets, Sanofi- Synthelabo Research

MEDICATION GUIDE AMBIEN® ( ām'bē-ən ) Tablets C-IV Ambien (zolpidem tartrate) Tablets, Sanofi- Synthelabo Research

AMBIEN ® (zolpidem tartrate) CIV Tablets

sanofi-aventis U.S., 55 Corporate Drive, PO Box 5925, Bridgewater, NJ 08807-0890 Tel. (908) 981-5000 - www.sanofi-aventis.com AMBIEN and AMBIEN CR DEAR HEALTHCARE PROFESSIONAL LETTER March 2007 Dear Healthcare Professional: Sanofi-aventis U.S. would like to inform you of important updated ...

Ambien (zolpidem tartrate) Tablets, Sanofi- Synthelabo Research

NDA 21774 FDA approved labeling text 4.5.10 In addition, patients should be advised to report all concomitant medications to the prescriber. Patients should be instructed to report events such as "sleep-driving" and other complex behaviors immediately to the prescriber. 17.3 Administration ...

Ambien (zolpidem)

Ambien (zolpidem) Generic name: Zolpidem Available strengths: 5 mg, 10 mg tablets Available in generic: No Drug class: Nonbenzodiazepine/sedative-hypnotic General Information Ambien (zolpidem), a sedative-hypnotic medication, is unrelated to the benzodiazepines or barbiturates and was approved ...

Informed Consent for Medication, F-24277, Ambien

Client Initial Date DEPARTMENT OF HEALTH SERVICES Division of Mental Health and Substance Abuse Services F-24277 (12/2010) STATE OF WISCONSIN 42 CFR483.420(a) (2) DHS 134.31(3)(o) DHS 94.03 & 94.09 s.51.61(1)(g) & (h ) INFORMED CONSENT FOR MEDICATION Dosage and / or Side Effect information last ...

ADVERSE REACTIONS ———————————————

HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use Ambien CR safely and effectively. See full prescribing information for Ambien CR.

, Zolpidem hemitartrate, SL80.0750-23N, SA02224

Material Safety Data Sheet Page 1 Issue Date: 26-July-01 AMBIEN ® 1. CHEMICAL PRODUCT AND COMPANY IDENTIFICATION Sanofi-Synthelabo Inc. 90 Park Avenue New York, NY 10016 Technical Information Telephone Number (Sanofi-Synthelabo Inc.): (800) 446-6267 EMERGENCY TELEPHONE NUMBER (CHEMTREC ...

Managing Patient Reimbursement Issues

AMBIEN® (zolpidem tartrate) is indicated for the short-term treatment of insomnia characterized by difficulties with sleep initiation. IMPORTANT SAFETY INFORMATION In elderly or debilitated patients, or in patients with hepatic insufficiency or dysfunction, the recommended dose of AMBIEN CR is 6.25 ...

Zolpidem Tartrate Use as Contributory Factor in Sinus Disease

The patient's symptoms completely resolved upon discontinuing her long-term zolpidem tartrate (Ambien) therapy for insomnia. She has been symptom free and off all rhinosinusitis and headache medications for 9 months.